Daehan New Pharm Co. Ltd (054670) — Cash Flow-to-Debt Ratio
Daehan New Pharm Co. Ltd (054670) has a Cash Flow-to-Debt Ratio of 0.04x as of September 2025, meaning its operating cash flow of ₩4.43 Billion could theoretically repay 0% of its total liabilities (₩122.10 Billion) in one year. See 054670 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Daehan New Pharm Co. Ltd Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for Daehan New Pharm Co. Ltd across 11 annual periods. Also explore net asset momentum of Daehan New Pharm Co. Ltd to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Daehan New Pharm Co. Ltd (2014–2024)
Year-by-year debt coverage analysis for Daehan New Pharm Co. Ltd. For market capitalisation and broader financial context, see Daehan New Pharm Co. Ltd (054670) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.20x | ₩18.95 Billion | ₩95.85 Billion | ▲ +6.3% |
| 2023 | 0.19x | ₩12.57 Billion | ₩67.57 Billion | ▼ -13.4% |
| 2022 | 0.21x | ₩14.25 Billion | ₩66.40 Billion | ▼ -2.7% |
| 2021 | 0.22x | ₩16.58 Billion | ₩75.18 Billion | ▲ +23.7% |
| 2020 | 0.18x | ₩13.55 Billion | ₩75.95 Billion | ▼ -47.9% |
| 2019 | 0.34x | ₩22.89 Billion | ₩66.84 Billion | ▲ +9.8% |
| 2018 | 0.31x | ₩20.47 Billion | ₩65.66 Billion | ▲ +1001.6% |
| 2017 | -0.03x | ₩-2.42 Billion | ₩70.09 Billion | ▼ -123.5% |
| 2016 | 0.15x | ₩8.75 Billion | ₩59.52 Billion | ▲ +4.4% |
| 2015 | 0.14x | ₩7.80 Billion | ₩55.43 Billion | ▼ -20.5% |
| 2014 | 0.18x | ₩10.02 Billion | ₩56.58 Billion | — |